Imcor Pharmaceuticals

Imcor Pharmaceuticals was a specialty pharmaceutical company focused on the development and commercialization of contrast agents for diagnostic imaging. The company's primary product was Imagent, an FDA-approved ultrasound contrast agent used to improve the characterization of the left ventricular endocardial border in patients with suboptimal echocardiograms. Imcor was formed through the merger of Photogen Technologies and the imaging assets of Alliance Pharmaceutical Corp. The company aimed to address the needs of the cardiology market by providing clearer diagnostic images for better patient management. However, due to financial challenges and limited market penetration, Imcor filed for Chapter 11 bankruptcy in 2006. Its assets were subsequently liquidated, marking the end of its operations as a standalone entity.